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OBJECTIVES: Type-2 diabetes patients with hypertension have
a high risk of developing nephropathy, with increased risks of
morbidity/mortality. Screening for, and treatment of nephropa-
thy, is currently suboptimal in France. We assessed the long-term
impact of screening for nephropathy followed by optimal anti-
hypertensive therapy in those in which nephropathy is detected
in France. METHODS: A Markov model projected lifetime
impacts of screening, identiﬁcation, and appropriate treatment
of nephropathy using semi-quantitative urine dipsticks in a
primary care setting, followed by treatment with irbesartan 300
mg added to conventional antihypertensives in a typical cohort
of hypertensive Type-2 diabetes patients. The model simulated
progression from no renal disease to end-stage renal disease
(ESRD). Probabilities and costs came from published sources.
Cumulative incidence of ESRD, years free of ESRD, life
expectancy (LE) and direct costs were projected. Second-order
Monte Carlo simulation was used to account for uncertainty in
multiple parameters. RESULTS: In a cohort of 1000 patients,
screening for nephropathy followed by optimal treatment
reduced cumulative incidence of ESRD from (mean ± SD) 11.0
± 1.7% to 6.5 ± 1.1%, increased number of ESRD-free years by
524 ± 80 years, increased undiscounted LE by 361 ± 60 years,
and reduced costs (discounted 3% annually) by €3,340,200 ±
799,800. Sensitivity analysis showed that screening was most
beneﬁcial in younger patients. CONCLUSIONS: In hypertensive
type-2 diabetes patients, screening for albuminuria followed by
optimal antihypertensive treatment that includes irbesartan 300
mg, is projected to lead to substantial reductions in the incidence
of ESRD, improvements in ESRD-free survival and life
expectancy, and overall cost savings.
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OBJECTIVE: Diabetes mellitus is an important chronic disease
with a growing prevalence that absorbs an ever increasing invest-
ment of resources. This study described the prevalence and the
cost of diabetic care using sampling claim data from the National
Health Insurance Program in Taiwan. METHOD: Five-year
(1997~2001) random sampling claimed database were prepared
by the National Health Research Institute, Taiwan, R.O.C. The
database contains 200,000 individuals’ longitudinal medical
claim data (0.9% Taiwan population), including outpatient and
inpatient care records. Patients with the ICD-9-CM code of 250
in their primary diagnosis column were used in the analysis.
RESULT: The prevalence rate of diagnosed diabetes patients
from 1997 to 2001 was 2.42%, 2.57%, 2.61%, 2.67% and
2.74%, respectively. This rate increased 12.8% in 5 years. The
average total direct medical cost per patient per year increased
18%, from 10,479 NTD in 1997 to 12,811 NTD in 2001.The
average number of outpatient visit increased from 7.4 in 1997
to 7.8 times in 2001. The average cost of outpatient care per
patient per year increased 27%, from 7680 NTD in 1997 to
10,016 NTD in 2001. The average inpatient care cost per hos-
pitalization increased 60%, from 29,908 NTD in 1997 to 48,071
NTD in 2001. Finally, the average total drug cost increased 31%,
from 5487 NTD in 1997 to 7209 NTD in 2001. All costs did
not adjust for inﬂation. CONCLUSION: The direct medical cost
for diabetes care increased rapidly in these 5 years, the rate
increased faster then the prevalence rate. The rate of drug cost
increased more then that of the total medical cost. Although the
representative of that sampling data needs veriﬁcation, the pre-
liminary data indicate that outpatient expenditure increased sig-
niﬁcantly. The appropriateness of resource utilization and quality
of diabetes care need more stringent management.
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OBJECTIVE: To estimate the cost of diabetes mellitus (DM) in
Spain by reviewing all available DM cost data. METHODS:
Outstanding articles and unpublished data were identiﬁed
through searches of PubMed, Spanish Medical Index, Spanish
databases for doctoral thesis, Ministry of Health, Carlos III
Health Institute, Spanish Health Technology Assessment Agen-
cies, SAMFYC diabetes group, Spanish Federation of Diabetes
Education Societies, and other DM sources from 1966 to
November 2004. All studies with outstanding information on
direct or indirect costs of DM diagnosis, treatment or complica-
tions were included (cost estimates in € of 2004). RESULTS: In
total, 32 cost-of-illness (COI) studies published between 1982
and 2004 met the inclusion criteria (16.354 DM patients), 23 of
them were performed with the prevalence method, 1 with the
incidence method and 6 were pharmacoeconomic analyses. Total
annual costs of DM in Spain would range between €685 and
€2.771 million (1.6–6.4% of the Spanish public health expendi-
ture). However, those results could underestimate the real DM
cost (according to CODE-2 study, the Type-2 DM cost in Spain
would be around 2.317 million € per year). The annual average
cost per patient with DM would range between 1.627 and
€3.982 for DM type-1 and €1.049–€5.091 for DM Type-2. The
cost of hospital admissions, primary care visits and antidiabetic
treatments would be 36–58%, 7–14% and 11–13% of the total
cost, respectively. The indirect costs would be 28–43% of total
DM costs. DM complications costs: serious hypoglycemia
(€3.469), hyperglycemia (€3.357), infections (€2.703), ketoaci-
dosis (€2.633), stroke (€4.091), ischemic cardiac disease
(€3.675), neuropathy (€3.540), nephropathy (€3.525) and
retinopathy (€2.109). CONCLUSIONS: The variability in the
costs estimates was due to the differences of the studies design.
To estimate the real cost of DM, a well designed COI prospec-
tive study is needed.
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OBJECTIVES: Despite the recent increase in incidence and
prevalence of Type-2 diabetes mellitus (T2DM) in Hong Kong,
the economic impact of the disease has never been investigated.
This study aims to estimate the total economic burden of a group
of T2DM patients attending a public hospital in Hong Kong
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using a prevalence-based cost-of-illness approach. METHODS:
A retrospective cohort observational study was conducted. The
direct medical costs incurred at the public hospital were collected
from a hospital electronic database. The other costs were esti-
mated using a standard Chinese questionnaire. The ﬁgures
obtained were extrapolated to estimate the total burden for the
whole T2DM population in Hong Kong. The study was con-
ducted from the perspective of a public hospital. RESULTS: Two
hundred and four patients with T2DM were randomly selected
to join this study and 147 were subsequently enrolled. Annual
total direct medical cost per patient was US$1492 in which the
government was shouldering 90.6%, while the patients only paid
for the remaining 9.4%. Among these, specialist outpatient clinic
visit costs and inpatient costs were the major cost drivers, which
contributed up to 39.6% and 43.0% of the overall cost, respec-
tively. The direct medical cost jumped dramatically, by 1.3 
times, if the patient had complications. The total government
direct medical cost for those without complication was
US$1254/patient/year, which would jump to US$1692 for
patients developing both microvascular and macrovascular com-
plications. T2DM was found to have signiﬁcant impact to the
local health care budget. It contributed to about 5.0% of the
total Hong Kong health care expenditure. CONCLUSIONS:
This study conﬁrmed T2DM and its complications pose a sig-
niﬁcant burden on the health care budget of Hong Kong. Slowing
the progression of the disease to the more advanced and costly
states should be cost saving.
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OBJECTIVE: To estimate the French hospital extra costs of car-
diovascular events (CVE) occurring in diabetic and non diabetic
patients. METHODS: Hospital stays were extracted from the
2003 national Diagnosis Related Group (DRG) including the
whole French stays (around 18 million records). Stays were
selected on the ICD-10 and/or procedures codes related to the
following events: stroke, myocardial infarction, unstable angina,
and coronary revascularisation. Diabetic patients were picked
out using secondary diagnosis related to diabetes mellitus (type
I and II). The level of resource consumption and average length
of stay were analyzed in both diabetic and non diabetic groups.
For the economic analysis, an adjustment method based on
national DRG costs (public and private hospitals) was used to
take into account extra length of stay of diabetic patients com-
pared with average DRG length of stay. RESULTS: Average
length of stay of diabetics was signiﬁcantly longer than non dia-
betics (stroke: 2.45 days, myocardial infarction: +1.48 days,
unstable angina: +1.25 days, revascularisation: 2.82 days; p <
0.001 for each). The mean number of medical procedures
recorded by stay was higher in the diabetic group (stroke: +0.51;
myocardial infarction: +0.80, unstable angina: +0.92, revascu-
larisation: +1.91; p < 0.001 for each) and diabetic patients had
more Intensive Care Unit transfer for myocardial infarction and
unstable angina (odd ratio diabetic versus non diabetic: 1.7 and
1.3; p < 0.001). Adjusted hospitalization costs of events for dia-
betic patients were the following: stroke (non fatal event): €5703,
myocardial infarction (non fatal event): €4721, unstable angina:
€4147, coronary revascularisation: €11,679. The overcosts of
diabetic patients for these events compared with average DRG
cost were respectively +23.9%, +10.4%, +6.1% and +9.1%.
CONCLUSION: Diabetic patients with CVE required higher
medical consumptions than non diabetic during hospital man-
agement. Extra costs associated with diabetes were estimated
and can be used in cost-effectiveness studies.
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OBJECTIVES: Cost study of diabetes therapy was conducted at
national level in 1997 but the introduction of health insurance
system and a lot of new medicines changed treatment patterns
as well the cost of therapy. The goal of this study is to analyse
the cost of diabetes therapy from the National Health Insurance
Fund (NHIF) point of view and to compare prescribing practice
with the previous study. METHODS: Information by the NHIF
electronic data base was collected at national level and repre-
sentative sample of 3410 and 2440 prescriptions for type-1 and
type-2 diabetic patients was analyzed. The observed patients
were also systematized for the available complications and their
treatment cost was calculated on the basis of NHIF tariffs. Man-
ufacturers’ information for the insulin market was collected and
compared with the prescribing information. RESULTS: The
number of diabetic patients increased since 1997 from 150,000
to 225,000 and patients on insulin therapy account for 35%.
The cost of the ambulatory treatment with peroral antidiabetics
account for €800,000 while expenditures for insulin are €32
million. The metformin was prescribed in 43% and glibenclamid
in 25% of prescriptions. It was revealed substantial growth in
the total insulin market from 610MU in 1997 to 969MU sold
in 2004 with prevailing prescribing of insulin mixtures in 59%.
Micro and macro vascular complications prevail in 97% of the
patients and account for 59% of expenditures paid for hospi-
talization and 20% of ambulatory expenditures. Expenditures
for insulin account for 18% of the cost of diabetes treatment
while per oral antidiabetics for less than 8%. CONCLUSION:
The cost of insulin treatment of one patient is close to cost
reported by similar European studies but Bulgaria delay with the
introduction of insulin analogues and it could affect the future
complications therapy.
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OBJECTIVES: Intensive insulin treatment is associated with an
increased risk of hypoglycemic events in type-1 diabetes. A recent
26-week randomized clinical trial demonstrated that basal/bolus
treatment of type-1 diabetic patients with insulin detemir +
insulin aspart (IDet/IAsp), compared to insulin glargine + insulin
aspart (IGlar/IAsp), led to a 72% lower risk of major hypo-
glycemic events (p < 0.05). METHODS: A validated model was
used to project long-term complications, quality-adjusted life
expectancy, long-term direct and indirect costs, and incremental
cost-utility ratios (ICURs) for IDet/IAsp versus IGlar/IAsp in
Austria and Germany. Markov modeling was used to describe
the incidence and progression of complications (cardiovascular
disease, neuropathy, renal and eye disease). Probabilities of com-
